• 1
    Inzucchi SE, Bergenstal RM, Buse JB et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012; 35: 136479.
  • 2
    UK Prospective Diabetes Study Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352: 85465.
  • 3
    UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352: 83753.
  • 4
    Holman RR, Paul SK, Bethel MA et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008; 359: 157789.
  • 5
    Schwartz D, Lellouch J. Explanatory and pragmatic attitudes in therapeutical trials. J Clin Epidemiol 2009; 62: 499505.
  • 6
    Treweek S, Zwarenstein M. Making trials matter: pragmatic and explanatory trials and the problem of applicability. Trials 2009; 10: 37.
  • 7
    Ware JH, Hamel MB. Pragmatic trials–guides to better patient care? N Engl J Med 2011; 364: 16857.
  • 8
    Levey AS, Greene T, Schluchter MD et al. Glomerular filtration rate measurements in clinical trials. Modification of Diet in Renal Disease Study Group and the Diabetes Control and Complications Trial Research Group. J Am Soc Nephrol 1993; 4: 115971.
  • 9
    CPMP, EMEA. Guideline on Clinical Investigation of Medicinal Products in the Treatment or Prevention of Diabetes Mellitus. http://www.ema europa eu/docs/en_GB/document_library/Scientific_guideline/2012/06/WC500129256. pdf (accessed 06 June 2013).
  • 10
    Food and Drug Administration. Guidance for Industry Diabetes Mellitus: developing Drugs and Therapeutic Biologics for Treatment and Prevention – Draft Guidance. (accessed 04 May 2013).
  • 11
    Wing RR, Lang W, Wadden TA et al. Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes. Diabetes Care 2011; 34: 14816.
  • 12
    National Institutes of Health. Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight Adults and Obesity in Adults. 1998. (accessed 07 June 2013).
  • 13
    Rosenbaum PR, Rubin DB. Reducing bias in observational studies using subclassification on the propensity score. J Am Stat Assoc 1984; 79: 51624.
  • 14
    Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika 1983; 70: 4155.
  • 15
    IDF. Website of the International Diabetes Federation. www idf org 2013. (accessed 07 June 2013).
  • 16
    Bader G, Geransar P, Schweizer A. Vildagliptin more effectively achieves a composite endpoint of HbA <7.0% without hypoglycaemia and weight gain compared with glimepiride after 2 years of treatment. Diabetes Res Clin Pract 2013 Mar 25; doi:pii: S0168-8227(13)00089-2. 10.1016/j.diabres.2013.03.011. [Epub ahead of print].
  • 17
    Bolli G, Dotta F, Colin L et al. Comparison of vildagliptin and pioglitazone in patients with type 2 diabetes inadequately controlled with metformin. Diabetes Obes Metab 2009; 11: 58995.
  • 18
    Bolli G, Dotta F, Rochotte E et al. Efficacy and tolerability of vildagliptin vs. pioglitazone when added to metformin: a 24-week, randomized, double-blind study. Diabetes Obes Metab 2008; 10: 8290.
  • 19
    Ferrannini E, Fonseca V, Zinman B et al. Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy. Diabetes Obes Metab 2009; 11: 15766.
  • 20
    Filozof C, Gautier JF. A comparison of efficacy and safety of vildagliptin and gliclazide in combination with metformin in patients with Type 2 diabetes inadequately controlled with metformin alone: a 52-week, randomized study. Diabet Med 2010; 27: 31826.
  • 21
    Garber AJ, Schweizer A, Baron MA et al. Vildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: a randomized, placebo-controlled study. Diabetes Obes Metab 2007; 9: 16674.
  • 22
    Liebl A, Mata M, Eschwege E. Evaluation of risk factors for development of complications in Type II diabetes in Europe. Diabetologia 2002; 45: S238.
  • 23
    Bruno G, Bonora E, Miccoli R et al. Quality of Diabetes Care in Italy: information From a Large Population-Based Multiregional Observatory (ARNO Diabetes). Diabetes Care 2012; 35: e64.
  • 24
    Perez Garcia M, Figueras A. The lack of knowledge about the voluntary reporting system of adverse drug reactions as a major cause of underreporting: direct survey among health professionals. Pharmacoepidemiol Drug Saf 2011; 20: 1295302.
  • 25
    Hazell L, Shakir SA. Under-reporting of adverse drug reactions: a systematic review. Drug Saf 2006; 29: 38596.
  • 26
    Ligueros-Saylan M, Foley JE, Schweizer A et al. An assessment of adverse effects of vildagliptin versus comparators on the liver, the pancreas, the immune system, the skin and in patients with impaired renal function from a large pooled database of Phase II and III clinical trials. Diabetes Obes Metab 2010; 12: 495509.
  • 27
    Schweizer A, Dejager S, Foley JE et al. Assessing the cardio-cerebrovascular safety of vildagliptin: meta-analysis of adjudicated events from a large Phase III type 2 diabetes population. Diabetes Obes Metab 2010; 12: 48594.
  • 28
    Schweizer A, Dejager S, Foley JE et al. Assessing the general safety and tolerability of vildagliptin: value of pooled analyses from a large safety database versus evaluation of individual studies. Vasc Health Risk Manag 2011; 7: 4957.